Krka Investor Day 2025

We had the pleasure of hosting the 11th Krka Investor Day, welcoming industry analysts and investors from around the world. We were delighted to meet with investment experts who closely follow Krka’s performance and provide investment recommendations, and make investment decisions. The meeting was attended by analysts and investors from the United Kingdom, the United States, Poland, Germany, Austria, Croatia, Serbia, North Macedonia, and Slovenia.

David Bratož, Member of the Management Board, presented our latest nine-month business developments and financial results, FY 2025 estimates and guidance for 2026, and unveiled our updated 2026–2030 Krka Group Development Strategy. The strategy firmly positions Krka among the world’s leading generic pharmaceutical companies, underscoring our ambition, competitive strengths, and commitment to sustainable growth.

Our mission remains clear: to serve patients by ensuring the timely supply of high-quality, safe, and effective medicines for the treatment of chronic diseases.

Additional perspectives were shared by Grega Hudovornik, PhD, Deputy Director of R&D, and Miha Borsellino, Sales Director, who provided valuable insights into our competitive edge in the development of generic medicines and our approach to navigating complex generics markets through our strong in-house marketing and sales network.

The event concluded with a guided tour of our state-of-the-art production facility Notol 2 led by Mrs Nataša Pevec, Director of Pharmaceutical Production, and a reception at Krkin Hram. The purpose of the meeting was to provide participants with direct access to Krka’s leadership, enabling a deeper and more comprehensive understanding of Krka’s business story. This objective was undoubtedly achieved, as the participants expressed their appreciation for both the event itself and the opportunity to strengthen relationships with our investor community.